drugset / Trial / NCT04632108
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1/2
Active not recruiting
199 enrolled
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Jiangsu Aosaikang Biopharmaceutical Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label Phase 1/2 study, the purpose of the trial is to assess the safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in patients suffering from advanced or metastatic solid tumors. Patients with gastric cancer/gastroesophageal junction adenocarcinoma and pancreatic cancer are preferred.
Timeline
- Start
- 2021-01-28
- Primary completion
- 2025-10-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASKB589 | Unknown | 0.3 mg/kg | — |
| Subject | ASKB589 | Unknown | 20 mg/kg | — |